R & D

AVEO was founded 10 years ago with the goal of developing a fundamentally new kind of cancer model designed to overcome many of the limitations of traditional models, and thereby improve the probability of success in developing new cancer drugs. We use our novel models to identify and validate target genes that drive tumor growth, to identify drugs that can block the function of these targets and to identify patients who are most likely to respond favorably to treatment with these drugs. We are using our Human Response Platform™, which encompasses our proprietary cancer models as well as various techniques developed in-house to aid in the discovery and development of new cancer therapies, to enrich outcomes in our ongoing clinical development programs and fuel our internal drug discovery engine.